1. Clinical Overview of LL-37
Molecule: LL-37 — 37–amino-acid C-terminal fragment of human cathelicidin antimicrobial protein (hCAP-18) · Classification: Host-defense peptide (HDP) with antimicrobial, antiviral, antifungal, antibiofilm, immunomodulatory, wound-healing, and angiogenic properties.
Physiologic Significance: LL-37 is produced by neutrophils, macrophages, keratinocytes, epithelial surfaces, and bone marrow progenitors. Essential for first-line immune defense, pathogen clearance, mucosal barrier protection, tissue repair, and immune system balancing.
2. Mechanisms of Action
2.1 Direct Antimicrobial Effects
Effective against Gram-positive bacteria, Gram-negative bacteria, MRSA, Pseudomonas, mycobacteria, fungi, parasites, and multiple viruses (enveloped and non-enveloped).
2.2 Immunomodulatory
Balances innate and adaptive immunity, enhances macrophage activity, regulates cytokines (IL-6, TNF-α, IL-10), reduces chronic inflammatory cascades, increases chemotaxis for controlled immune response.
2.3 Mucosal & Epithelial Repair
Accelerates healing in skin, GI tract, nasal/sinus mucosa, respiratory surfaces, and urogenital tissues via angiogenesis enhancement, collagen deposition, re-epithelialization, and wound contraction regulation.
2.4 Anti-Biofilm Activity
Biofilms cause chronic, recurrent infections. LL-37 disrupts biofilm formation, EPS matrices, and bacterial quorum sensing — crucial for chronic sinusitis, chronic UTI, Lyme co-infections, Candida biofilms, and infected wounds.
3. Evidence Summary — Clinical Domains
3.1 Chronic & Recurrent Infections
Chronic sinusitis, chronic bronchitis, chronic UTIs, Lyme-related infections, biofilm-associated infections, non-healing wounds, skin infections.
3.2 Wound Healing & Regenerative Medicine
Surgical incisions, burns, ulcers, diabetic wounds, pressure injuries — via increased angiogenesis, improved collagen remodeling, reduction in microbial load.
3.3 Dermatology & Aesthetic Medicine
Acne (antimicrobial + anti-inflammatory), post-procedure healing, rosacea (modulates innate immunity), psoriasis and eczema (adjunct), chronic dermatitis.
3.4 Immune System Optimization
Normalizes innate immune dysfunction, chronic inflammation, poor pathogen clearance. Particularly useful for immunosenescence, chronic inflammatory conditions, frequent infections.
3.5 Respiratory & Sinus Applications
Chronic rhinosinusitis, allergic fungal sinusitis, recurrent bronchitis, post-viral recovery, chronic cough (inflammatory phenotype).
4. Administration Routes & Protocols
4.1 Subcutaneous (Most Common)
Moderate Infection: 300–500 mcg SC, 3× weekly
Aggressive Anti-Biofilm: 500–800 mcg SC, 3–5× weekly (4–6 week course)
Cycle: 4–12 weeks · Maintenance: 1–2× weekly as needed
4.2 Intramuscular (IM)
4.3 Topical
Wound Care: 0.5–1% hydrogel dressing, 1–2× daily
Applications: Non-healing wounds, acne, post-microneedling, chronic dermatitis, cellulitis adjunct
4.4 Intranasal (Chronic Sinusitis)
4.5 Nebulized (Advanced/Specialty Only)
5. Clinical Decision Trees
Decision Tree 1 — Is LL-37 Indicated?
Chronic or recurrent infection present? → YES → LL-37 appropriate
Biofilm-associated or antibiotic-resistant? → Strong LL-37 indication
Non-healing wound or ulcer? → LL-37 + wound-care protocol
Skin inflammation or acne? → Topical LL-37 ± SC
Chronic sinusitis or respiratory inflammation? → Intranasal LL-37
Autoimmune disease? → Case-by-case evaluation
Decision Tree 2 — Dosing Strategy
Mild infection / immune dysfunction? → 100–300 mcg SC 3× weekly
Moderate chronic infections? → 300–500 mcg SC 3× weekly
Severe / biofilm? → 500–800 mcg SC 3–5× weekly
Dermatologic? → Topical LL-37 0.1–0.5%
Chronic sinusitis? → Intranasal 50–100 mcg each nostril
6. Integrated Treatment Archetypes
Archetype A — Chronic Sinusitis & Biofilm
Systemic: LL-37 300–500 mcg SC 3× weekly + KPV 250–500 mg/day + Glutathione IV 1–2× weekly
Local: Intranasal LL-37 BID + saline/budesonide rinses
Archetype B — Chronic Wound / Ulcer
Local: LL-37 0.5–1% gel BID + GHK-Cu serum + TB-500 SC near wound margins
Systemic: LL-37 SC 300–500 mcg + Glutathione for detox & redox
Archetype C — Dermatology & Aesthetic Post-Procedure
Topical: LL-37 0.1–0.3% post-needling or RF + GHK-Cu nightly
Systemic: KPV oral for inflammation control
Archetype D — Immune Optimization
Systemic: LL-37 100–300 mcg SC + NAD+ weekly + KPV oral + Glutathione IM/IV
7. Expected Clinical Timeline
Week 1–2: Pathogen load reduction; wound improvement
Week 2–4: Significant improvement in chronic infections
Week 4–12: Enhanced immune resilience and reduced recurrence
8. Contraindications & Adverse Effects
Absolute Contraindications
- Known hypersensitivity
- Pregnancy/lactation (insufficient data)
Relative Contraindications
- Autoimmune disease (immune stimulation potential)
- Severe asthma (nebulized caution)
- Severe inflammatory flare states
Adverse Effects
Injection-site pain, Herxheimer-like reaction (detox flare), temporary fatigue, mild fever/chills (immune activation), nasal burning (intranasal). Most side effects are mild and transient.
9. Monitoring
- Infection symptoms
- Wound healing progression
- Sinus/respiratory function
- Inflammatory markers (CRP, ESR)
- Liver function (if long-term therapy)
Legal Disclaimer
This document is provided solely for educational and informational purposes. LL-37 (Human Cathelicidin Antimicrobial Peptide) and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use. Peptide Protocol Portal makes no representations or warranties. Clinical decisions remain the sole responsibility of the licensed practitioner. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable for any damages or adverse outcomes. Use at your own risk.
References — LL-37 Clinical Reference Guide
Provider Access Required
Create a provider account to read the full clinical guide for LL-37 (Human Cathelicidin).